OQROGet OQRO Pro
Insider trade

Danaher Corporation (DHR)Director sold ~$747K

Teri List, Director at Danaher Corporation, sold ~$747K of Danaher Corporation shares.

~$747K
Approx. value · 3,298 sh @ $226.50
21K
Holds after · shares reported
Traded
Nov 18, 2025
Filed
Nov 19, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Apr 28, 2025CongressDisclosed purchase of DHR — reported range $1,001 - $15,000
  2. Sep 3, 2025CongressDisclosed purchase of DHR — reported range $1,001 - $15,000
  3. Sep 25, 2025CongressDisclosed sale of DHR — reported range $1,001 - $15,000
  4. Oct 7, 2025CongressDisclosed purchase of DHR — reported range $1,001 - $15,000
  5. Oct 21, 2025Company filing · Form 8-K · ResultsReported its results
  6. Oct 31, 2025Insider · 1 personInsiders: 3 sales (~$129.6M)
  7. Nov 6, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On November 6, 2025, John T. Schwieters notified Danaher’s Board of Directors (“Board”) that he has decided not to stand for reelection at the Company’s 2026 annual meeting of shareholders (“2026 Annual Meeting”), and will retire from the Danaher Board as of the 2026 Annual Meeting.”
  8. Nov 7, 2025FDARecall: Access 2 Reaction Vessels, individual, disposable, plastic tubes used to process patient, quality control and calibration samples on the Access 2 Immunoassay s…
  9. Nov 10, 2025FDARecall: COULTER DxH Diluent, REF 628017 COULTER DxH ECO Diluent REF C67250 For use as an isotonic buffered diluent in conjunction with a cyanide-free lytic agent for c…
  10. Nov 10, 2025Insider · 1 personInsiders: 2 sales (~$1.1M)
  11. Nov 11, 2025InsiderCFO sold ~$3.47M of DHR shares in the open market
  12. Nov 12, 2025Insider · 2 peopleInsiders: 6 sales (~$100.3M)
  13. Nov 13, 2025CongressDisclosed partial sale of DHR — reported range $1,001 - $15,000
  14. Nov 17, 2025FDAFDA device clearance: Access Rubella IgG
  15. Nov 18, 2025 · this disclosureInsiderDirector sold ~$747K of DHR shares in the open market

What came next

  1. Nov 25, 2025Insider · 1 personInsiders: 2 sales (~$9.4M)
  2. Nov 26, 2025FDARecall: Beckman Coulter UniCel Dxl 600, Part numbers: A71460, A71461, A30260; Immunoassay Method, Troponin Subunit
  3. Nov 26, 2025FDARecall: Beckman Coulter UniCel Dxl 800, Part numbers: 973100, A71456, A71457, A25288; Immunoassay Method, Troponin Subunit
  4. Dec 8, 2025FDARecall: The LDL-Cholesterol assay is comprised of two distinct phases. In phase one a unique detergent solubilizes cholesterol from non-LDL- lipoprotein particles. Thi…
  5. Dec 18, 2025CongressDisclosed sale of DHR — reported range $1,001 - $15,000
  6. Dec 23, 2025FDARecall: CellMek SPS Sample Preparation System, REF: C44603, with software
  7. Jan 12, 2026Company filing · Form 8-K · ResultsReported its results
  8. Jan 16, 2026FDAFDA device clearance: Xpert GI Panel
  9. Jan 27, 2026FDAFDA device clearance: Access anti-HAV IgM
  10. Jan 28, 2026Company filing · Form 8-K · ResultsReported its results
  11. Jan 30, 2026FDARecall: CHEMISTRY ANALYZER AU5800, REF: B96697, B96698, B23279, B23280, B23281
  12. Jan 30, 2026FDARecall: DxC 700 AU, REF: B86444, B86446
  13. Jan 30, 20265% stakeThe Vanguard Group reported a passive stake (13G) of 8.6%
  14. Feb 5, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On February 5, 2026, Jessica L. Mega notified Danaher Corporation’s (“Danaher”) Board of Directors (“Board”) of her retirement from the Board as of February 5, 2026, due to commitments related to her other professional obligations.”
  15. Feb 19, 2026FDAFDA device clearance: Access anti-HBc Total
  16. Feb 19, 2026InsiderOfficer sold ~$275K of DHR shares in the open market
  17. Feb 20, 2026FDAFDA device clearance: Xpert Hemorrhagic Fever
  18. Mar 13, 2026FDAFDA device clearance: Access anti-HBc IgM
  19. Mar 16, 2026FDARecall: Access Total T4 Calibrator, Catalog No. 33805
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Danaher Corporation

For Danaher Corporation, OQRO holds 3 insider filings (SEC Form 4 or Form 144), 3 Congress trade reports and 86 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its DHR page.

Other recent filings by Teri List, Director

The full history of Teri List, Director is on the profile page.

How this filing works

Other disclosures at Danaher Corporation

Everything OQRO holds on this company is on its DHR page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data